Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 10/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19577395 | 0.94 | ATF4 (0.62) | ATF4KMT2AATMCYP1A2CYP2C9 | |
| SCHEMBL19577397 | 0.94 | ATF4 (0.62) | ATF4KMT2AATMKDM4ENPC1 | |
| SCHEMBL19577394 | 0.90 | ATF4 (0.57) | ATF4NPC1 | |
| SCHEMBL19577393 | 0.89 | ATF4 (0.56) | ATF4KDM4E | |
| SCHEMBL19577396 | 0.89 | PPARD (0.56) | ATF4KMT2ANPC1MEN1 | |
| SCHEMBL22395386 | 0.85 | ATF4 (0.61) | ATF4 | |
| SCHEMBL19569415 | 0.84 | ATF4 (0.80) | ATF4KDM4ENPC1 | |
| SCHEMBL20722101 | 0.84 | ATF4 (0.75) | ATF4KMT2ANPC1MEN1 | |
| SCHEMBL20974142 | 0.83 | ATF4 (1.00) | ATF4KMT2ANPC1MEN1 | |
| SCHEMBL24116911 | 0.83 | ATF4 (0.56) | ATF4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240173307-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-05-30 | — | — | US | disclosed |
| CN-112204006-B | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2023-11-28 | — | — | CN | disclosed |
| EP-3704089-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2023-07-19 | — | — | EP | disclosed |
| EP-3452453-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2022-04-13 | — | — | EP | disclosed |
| EP-3452453-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2022-04-13 | — | — | EP | disclosed |
| US-20210393599-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2021-12-23 | — | — | US | disclosed |
| US-20210393599-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2021-12-23 | — | — | US | disclosed |
| US-10836725-B2 | Modulators of the integrated stress pathway | ABBVIE INC. (US) | 2020-11-17 | — | — | US | disclosed |
| US-10836725-B2 | Modulators of the integrated stress pathway | ABBVIE INC. (US) | 2020-11-17 | — | — | US | disclosed |
| EP-3704089-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2020-09-09 | — | — | EP | disclosed |
| US-20190194135-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC | 2019-06-27 | — | — | US | disclosed |
| US-20190194135-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC | 2019-06-27 | — | — | US | disclosed |
| EP-3452453-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2019-03-13 | — | — | EP | disclosed |
| WO-2017193041-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES (US) | 2017-11-09 | — | — | WO | disclosed |
| WO-2017193041-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES (US) | 2017-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10836725-B2 | Modulators of the integrated stress pathway | ATF4, ATF1, DDIT3 | ATF4 1/4885KMT2A 4320/4885ATM 114/4885 |
| US-20190194135-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ATF4 1/4885KMT2A 4320/4885ATM 114/4885 |
| US-20240173307-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ATF4 1/4885KMT2A 4320/4885ATM 114/4885 |
| US-20210393599-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ATF4 1/4885KMT2A 4320/4885ATM 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.